Inflammatory Bowel Disease (IBD) is a chronic disease impacting nearly 1.2 million Americans.1 Developments in treatment, such as biologics, have greatly improved quality of life for patients and advancements in laboratory testing are helping to support diagnosis and optimize therapy. Med lab offers leading expertise and comprehensive testing services to support physicians in the management of IBD patients.
There are an estimated 84 million adults 18 years and older in the U.S. who are prediabetic or at risk for developing diabetes.1 Prediabetes is characterized as higher than normal glucose levels but not high enough to meet criteria for diabetes.2 It is associated with –
Med lab is the exclusive national laboratory integrated within The Recovery Platform♦, allowing for seamless access to Med lab’s medication-assisted treatment (MAT) monitoring services. The combination of Med lab’s testing and The Recovery Platform’s software supports compliance with medication-assisted treatment, and helps patients stay on track with their recovery.
Recently, there has been increased discussion around non-fasting cholesterol testing. This is an appropriate dialogue because testing needs to be convenient and easy to help facilitate patient compliance. However; it is important that non-fasting cholesterol testing is appropriate for the clinical circumstances in which it is to be used.